Skip to NavigationSkip to content

Gilead buys Novartis' herpes, flu and cold virus preclinical programmes

Published on 23/07/19 at 09:38am

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat influenza, herpes and human rhinovirus, the virus that causes the common cold.

The deal will see Gilead acquire the exclusive global rights to develop and commercialise novel small molecules against the three undisclosed targets.

The deal will see Novartis receive an upfront payment of an undisclosed amount and up to $291 million in milestone payments on reaching commercial and developmental milestones.

“Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said Dr John McHutchison, Gilead’s Chief Scientific Officer and Head of Research and Development.  

The deal will see Gilead build on its core competency of virology and infectious diseases. The Foster City-firm’s antiviral portfolio includes some of the most widely sued medicines for Hepatitis B (HBV), Hepatitis C (HCV) and HIV. The deal represents Gilead's move into mass market therapeutic areas. 

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches